Engineered chemokines, resistant to cancer-mediated post-transcriptional modifications, as drugs to improve cancer immunotherapy

Ofer Mandelboim; Angel Porgador

doi:10.1073/pnas.2507821122

Engineered chemokines, resistant to cancer-mediated post-transcriptional modifications, as drugs to improve cancer immunotherapy

Ofer Mandelboim
, Angel Porgador

The Shraga Segal Department of Microbiology and Immunology

Research output: Contribution to journal › Comment/debate

Original language	English
Article number	e2507821122
Journal	Proceedings of the National Academy of Sciences of the United States of America
Volume	122
Issue number	21
DOIs	https://doi.org/10.1073/pnas.2507821122
State	Published - 27 May 2025

ASJC Scopus subject areas

General

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1073/pnas.2507821122

Cite this

@article{52639451f620464b9d0293d7949cbb66,

title = "Engineered chemokines, resistant to cancer-mediated post-transcriptional modifications, as drugs to improve cancer immunotherapy",

author = "Ofer Mandelboim and Angel Porgador",

year = "2025",

month = may,

day = "27",

doi = "10.1073/pnas.2507821122",

language = "English",

volume = "122",

journal = "Proceedings of the National Academy of Sciences of the United States of America",

issn = "0027-8424",

publisher = "National Academy of Sciences",

number = "21",

}

TY - JOUR

T1 - Engineered chemokines, resistant to cancer-mediated post-transcriptional modifications, as drugs to improve cancer immunotherapy

AU - Mandelboim, Ofer

AU - Porgador, Angel

PY - 2025/5/27

Y1 - 2025/5/27

UR - https://www.scopus.com/pages/publications/105005897690

U2 - 10.1073/pnas.2507821122

DO - 10.1073/pnas.2507821122

M3 - Comment/debate

C2 - 40388627

AN - SCOPUS:105005897690

SN - 0027-8424

VL - 122

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

IS - 21

M1 - e2507821122

ER -

Engineered chemokines, resistant to cancer-mediated post-transcriptional modifications, as drugs to improve cancer immunotherapy

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this